Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug

Enlivex pledged commercially reasonable efforts to hold the shareholder vote within 60 days, while the second $400 million remains optional. The post Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug appeared first on CryptoSlate.